



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## HIV-1 inhibitor-66

<b>Cat. No.:</b>	HY-162461
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>15</sub> BrClF <sub>3</sub> N <sub>4</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	555.73
<b>Target:</b>	Reverse Transcriptase; HIV
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcription inhibitor (NNRTI). HIV-1 inhibitor-66 shows inhibitory activity against wild-type HIV-1 reverse transcriptase with an IC <sub>50</sub> of 40 nM <sup>[1]</sup> .
<b>In Vitro</b>	HIV-1 inhibitor-66 (compound 10n) inhibits wild-type (WT) HIV-1 (IIIB) and NNRTIs-resistant strains, with EC <sub>50</sub> values of 0.009 μM, 0.011 μM, 0.013 μM, 0.018 μM, 0.703 μM, 0.013 μM, 17.7 μM, and 0.059 μM against HIV-1 IIIB, L100I, K103N, Y181C, Y188L, E138 K, F227L/V106A, and RES056 (K103N/Y181C), respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	HIV-1 inhibitor-66 (compound 10n) demonstrates excellent pharmacokinetic profile (T <sub>1/2</sub> =5.09 h, F=108.96%) in rats. HIV-1 inhibitor-66 is verified to have no in vivo acute or subacute toxicity (LD <sub>50</sub> >2000 mg/kg) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Yanying Sun, et al. Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV-1 NNRTIs. J Med Chem. 2024 Apr 25;67(8):6570-6584.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA